Silvio Danese1, Gionata Fiorino2, Pierre Michetti3. 1. IBD Center, Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy. Electronic address: sdanese@hotmail.com. 2. IBD Center, Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy. 3. IBD Center, Gastroenterology, La Source-Beaulieu, Lausanne, Switzerland.
Abstract
BACKGROUND: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies. METHODS: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.
BACKGROUND: Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies. METHODS: A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.
Authors: Cécile Rémuzat; Anna Kapuśniak; Aleksandra Caban; Dan Ionescu; Guerric Radière; Cyril Mendoza; Mondher Toumi Journal: J Mark Access Health Policy Date: 2017-04-28